All In Biotech

Drug Trial Radar · NCT06839235

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

23

Planned (sponsor's estimate)

Start

Jun 16, 2025

Primary completion

Mar 2029

Study completion Feb 2043

Sponsor

Lead sponsor
Arbor BiotechnologiesIndustry
Sponsor type
Industry
First posted
Feb 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pediatric participants will be treated with the recommended dose. Following the first Study Period, participants will start Study Period 2, a long-term monitoring program to comply with local and national requirements.

Conditions

  • Primary Hyperoxaluria Type 1 (PH1)

Interventions

  • ABO-101Drug

    Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs), including ABO-101-related TEAEs and serious adverse events (SAEs)Time frame: Up to 6 months

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Nucleus Network

    Saint Paul, Minnesota · Withdrawn

  • Hospices Civils de Lyon- Hôpital Femmes Mères Enfants

    Lyon, France · Not yet recruiting

  • Kindernierenzentrum Bonn

    Bonn, Germany · Not yet recruiting

  • Heidi Chaker

    Sfax, Tunisia · Recruiting

  • Queen Elizabeth Hospital Birmingham

    Birmingham, United Kingdom · Recruiting

  • Royal Free Hospital

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.